GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regeneron Pharmaceuticals REGN · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500Nasdaq-100

Compare

919.96

+1.73%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Regeneron Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Regeneron Pharmaceuticals is based in Tarrytown, New York and is incorporated in New York. Its shares trade on Nasdaq under the ticker REGN. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $14.34bn and net income of $4.50bn. At that date it held total assets of $40.56bn and shareholders' equity of $31.26bn.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Jan 1991
Employees
15,410
Head office
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
Incorporated in
NY
Classification
Pharmaceutical Preparations
Filer status
Large accelerated filer

Leadership

Pay as last reported

  • Dr. Leonard SchleiferCo-Chairman of the Board, President, Chief Executive Officer, Founder, since 1988$6.8m
  • Dr. George YancopoulosCo-Chairman of the Board, President, Chief Scientific Officer$6.8m
  • Mr. Christopher FenimoreChief Financial Officer, Executive Vice President - Finance$6.3m
  • Mr. Joseph LaRosaExecutive Vice President, General Counsel, Secretary$7.1m
  • Mr. Daniel Van PlewExecutive Vice President, General Manager - Industrial Operations and Product Supply$8.7m
  • Ms. Marion McCourtExecutive Vice President - Commercial$6.9m
  • Dr. Andrew MurphyExecutive Vice President - Research$8.4m
  • Mr. Jason PitofskyVice President, Controller
  • Ms. Christine PoonLead Independent Director$769,772
  • Dr. Bonnie BasslerIndependent Director$709,772
  • Dr. Michael BrownIndependent Director$724,772
  • Dr. N. Anthony ColesIndependent Director$699,772

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
63
Environment
62
Social
86
Governance
42
Direct emissions (scope 1)
80,300 t
Energy emissions (scope 2)
57,000 t
Value chain emissions (scope 3)
1,344,820 t
Women in the workforce
50%
Carbon reduction policy
No
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Regeneron Pharmaceuticals Inc has several strengths that contribute to its success in the market. These strengths include:

Weaknesses

  • Despite its strengths, Regeneron Pharmaceuticals Inc also has certain weaknesses that need to be addressed. These weaknesses include:

Opportunities

  • Regeneron Pharmaceuticals Inc can capitalize on several opportunities to further enhance its market position. These opportunities include:

Threats

  • Regeneron Pharmaceuticals Inc also faces certain threats that could impact its business and growth prospects. These threats include:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.